Assessment of oxygenation and comorbidities improves outcome prediction in patients with community-acquired pneumonia with a low CRB-65 score.
J Intern Med. 2015 Jan 16;
Authors: Kolditz M, Ewig S, Schütte H, Suttorp N, Welte T, Rohde G, The CAPNETZ study group
BACKGROUND: Addition of assessment of comorbid diseases ('D') and oxygen saturation ('S') to the CRB-65 score has been recommended to improve its accuracy for risk stratification in community-acquired pneumonia (CAP). The aim of the present study was to validate the resulting DS-CRB-65 score in a large cohort of patients with CAP.
METHODS: A total of 4432 patients prospectively enrolled in the CAPNETZ cohort were included in the present study. Predefined endpoints were 28-day mortality, requirement for mechanical ventilation or vasopressors (MV/VS) and requirement for MV/VS or intensive care unit admission (MV/VS/ICU). Receiver operating characteristic curve analysis was used to determine the accuracy of the CRB-65 score and the addition of D (extra-pulmonary comorbidities) and S (oxygen saturation <90% or partial pressure of oxygen <8 kPa). Binary logistic regression and the method of Hanley and McNeil were used to compare the criteria.
RESULTS: The mortality rate was 4.0%, and 4.2% of patients required MV/VS and 6.6% required MV/VS/ICU. After multivariate analysis, D and S independently added to the CRB-65 criteria for mortality prediction, but only S improved prediction of MV/VS and MV/VS/ICU (P < 0.001 for both). The area under the curve of the CRB-65 score was significantly improved by adding D and S for all endpoints (P < 0.02). Among patients who died or required MV/VS despite a CRB-65 score of 0, 64-80% would have been identified by the DS-CRB-65 score.
CONCLUSIONS: The addition of assessment of oxygenation and comorbidities significantly improved the prognostic accuracy of the CRB-65 score. Consequently, the DS-CRB-65 score may have a useful role in risk stratification algorithms for CAP. This article is protected by copyright. All rights reserved.
PMID: 25597400 [PubMed - as supplied by publisher]